Company Interview / Therapeutic breakthrough? Alterity CEO on MSA progress

Alterity Therapeutics (ASX: ATH) CEO David Stamler shares insights on the company's recent phase two study, showing promising results for treating Multiple System Atrophy (MSA).

The data, presented at various conferences, suggest the drug slows disease progression and has a strong safety profile.

Alterity is preparing for regulatory discussions to advance the drug, aided by the FDA's Fast Track designation. This designation allows accelerated approval processes, crucial for bringing this novel treatment to patients.

David remains optimistic about Alterity's position given MSA's unmet medical need. Discussing potential impacts of US governmental policies on pharmaceuticals, David dismisses significant concerns, emphasising Congress's role in such decisions.

Financially, Alterity is in a strong position, having raised $40 million, and is focused on advancing trials and regulatory approvals swiftly.